Laboratory Monitoring of Cyclosporine Pre-dose Concentration (C0) After Kidney Transplantation in Isfahan
Authors
Abstract:
Background: Cyclosporine is the main immunosuppressive agent used in organ transplantation which leads to considerable improvement in graft survival. The large inter- and intra- patient variability in cyclosporine pharmacokinetics coupled with the agent’s narrow therapeutic index and adverse effects necessitate therapeutic monitoring of cyclosporine blood levels. Objective: The aim of this study was to determine the extent of variability following oral administration of cyclosporine after kidney transplantation, and provide guidelines for administration of cyclosporine in Isfahan/Iran Methods: The results of 2163 cyclosporine pre-dose blood samples obtained from 647 kidney transplant recipients (208 females, 439 males) with a median age of 34 years (range 11-54 years) were studied. Concentration of cyclosporine in the whole blood was determined by a radioimmunoassay using monoclonal antibodies specific for the drug. Statistical analyses were performed using SPSS. Results: The frequency distribution of C0 and daily oral dosage of cyclosporine exhibited wide interindividual variability. Cyclosporine oral dosage regimen ranged from 100 mg to 400 mg. Trough cyclosporine blood concentration (C0) ranged from 18 ug/l to 1400 ug/l. The results of cyclosporine whole blood levels in 56% were always below the suggested therapeutic range (less than 200 ug/l) and in 14% of the samples seemed to be associated with the occurrence of toxic side effects. There were no significant differences in the median trough levels of kidney recipients according to gender (p = 0.36). Conclusion: For long-term management of kidney transplant recipients and in order to further optimize the use of cyclosporine, it is essential to standardize laboratory monitoring and clinical investigation of this agent.
similar resources
laboratory monitoring of cyclosporine pre-dose concentration (c0) after kidney transplantation in isfahan
background: cyclosporine is the main immunosuppressive agent used in organ transplantation which leads to considerable improvement in graft survival. the large inter- and intra- patient variability in cyclosporine pharmacokinetics coupled with the agent’s narrow therapeutic index and adverse effects necessitate therapeutic monitoring of cyclosporine blood levels. objective: the aim of this s...
full textThe Relationship between the Plasma Level of Cyclosporine-A and Drug Dose in Patients of Kermanshah Kidney Transplantation Center
Background: Nowadays the main problem in transplantation is the complexity of host immune system protection against the immunological and destructive reactions of the transplanted organ. High serum level of the immunosuppressive drug may cause toxicity and low serum level leads to the rejection of the transplanted organ. Cyclosporine has been known as the most effective immunosuppressive drug. ...
full textCyclosporine C0- versus C2-monitoring over three years in maintenance heart transplantation.
INTRODUCTION There is an ongoing discussion as to whether monitoring of cyclosporine (CsA)-based immunosuppression with plasma levels two hours after medication intake (C2) offers clinical benefit over the measurement of CsA trough levels (C0) in patients after heart transplantation (HTx). In particular, data from long-term maintenance patients are not available. METHODS C0 monitoring was per...
full textchange of cyclosporine absorption over the time after kidney transplantation
background although the immunosuppressant cyclosporine (csa) is widely used after kidney transplantation over the long term, there is still no firm consensus on the best way to monitor of csa blood levels. objectives cyclosporine (csa) assay is critical for the management of renal transplant recipients due to inter– and intra–patient variation in csa absorption and metabolism. patients and meth...
full textNINE CASES OF MALIGNANCY AFTER KIDNEY TRANSPLANTATION
Renal transplantation is considered one of the best long-term therapies for chronic renal failure, but unfortunately the incidence of malignancy significantly increases in renal transplant recipients. We analyzed nine cases of malignancy in 200 renal transplant recipients occurring in a 12-year follow-up in Imam hospital of Tehran University, Tehran, Iran. According to this study, the organ...
full textMy Resources
Journal title
volume 28 issue 2
pages 81- 85
publication date 2015-10-28
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023